Rubicon Research Limited

₹1,731As of Sun 8 Nov 2026, 12:00 UTC
NSE:RUBICONHealthcare
Country India
PE (Fwd) •••
TSR 10Y CAGR —
Div yield 0.09%
ROE 31.25%
Drug Manufacturers (General)
Beta (5Y) —
PE TTM 88.97
TSR TTM 180.27%
Mkt cap ₹286.5B
ROIC 23.69%
SE Grade™
Value
Quality
Moat
Consensus
Reference
₹1,685
(2.64%)
(86.94%)
Hold 3|11|7|7|12
3Q26
4Q26
1Q27
2Q27
Earnings per share₹
27.80
30.61
32.00
31.63
(1.39%)
12.87%
13.30%
14.85%
Revenue₹B
31.12
31.18
32.87
33.90
8.93%
3.98%
12.53%
14.04%
Peers (US$2.925B)
Cap (US$)
PE
4.564B
37.29x
1.879B
20.53x
3.383B
19.35x
Capital
TTM
5Y
10Y
Leveragex
1.578
0.118
0.126
EBIT/Intx
1.172
0.647
0.434
Own earn%
(109.67)
(45.53)
(48.79)
Sh yield%
45.57
34.71
38.59
Owners
Insiders/Inst%
6.75
41.33
Short interest%
1.09
SBC / revenue%
3.54
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
11–14
$1 testx
—
Incr. ROIC%
3